Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United States patent (No. 8,314,100), titled "1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives."
This new patent covers Rexahn's quinoxalinyl-piperazine compounds, the process for the preparation of such compounds and their pharmaceutical composition. The patent includes Rexahn's RX-5902, a first-in-class p68 helicase inhibitor, that is an orally available new chemical entity exhibiting potent antitumor properties in several types of tumors. RX-5902 has also shown to possess strong anti-proliferative activity against known anti-cancer drug-resistant cancer cells, and a synergistic effect with known anti-cancer drugs.
Rexahn has previously been awarded patents for quinoxalinyl-piperazine compounds in Europe, Australia, Canada and Mexico.
"We are very pleased to gain this important intellectual property protection for this exciting class of compounds in oncology. This patent is significant step forward in the development of RX-5902, and further strengthens our overall global intellectual property position in oncology," said Rick Soni, President of Rexahn.
Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers